Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Months After COVID-19 Infection, Rheumatic-Like Symptoms Persist

Mary Beth Nierengarten  |  Issue: April 2021  |  April 16, 2021

Dr. Chang

Dr. Chang

Ann Marie Chang, MD, associate professor, emergency medicine, Jefferson University Hospitals, Philadelphia, also underscored that a better understanding of patients who experience persistent symptoms post-COVID-19 infection may help focus more attention on other conditions with similar long-term symptoms, such as chronic fatigue syndrome, for which a better understanding has long been needed.

Dr. Chang is leading efforts at Jefferson University to enroll patients in a U.S. National Institutes of Health study, the Innovative Support for Patients with SARS-CoV-2 Infections (COVID-19) Registry (INSPIRE), to better understand the range of persistent symptoms of long-haulers.11

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As both a physician who has treated COVID-19 patients and someone with firsthand experience of persistent symptoms after recovering from acute COVID-19 infection in March 2020, Dr. Chang says she hopes the study will provide needed information on questions about why some patients develop these symptoms, how to treat those who do and how to prevent the onset of persistent symptoms.

“Right now, as a physician, it feels like riding a bike that we’re building at the same time—there is such a rapid reassessment of recommendations for a condition that we don’t necessarily know how to treat,” Dr. Chang said in a Feb. 10 press release.12

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As someone who knows what it feels like to have a condition without a clear diagnosis and treatment, she stressed the need for clinicians to recognize the condition.

“For patients whose quality of life has been so severely impacted, it’s really scary to hear from their doctors that we just don’t know what to do for them, and we don’t know when their symptoms will end—is it a year, two years, lifelong? We just don’t know,” Dr. Chang said.12


Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.

More Research Underway

A new U.S. National Institutes of Health initiative is underway to better understand the many unknowns about long-term complications of SARS-CoV-2 infection. The Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative and Investigator Consortium is seeking applications to support research on the long-term complications of SARS-CoV-2 infection. For more information click here.

Patient Resources

  • Survivor Corps. Online resources for COVID-19 survivors, including national database of Post-COVID Care Centers (PCCC) by state
  • Global Healthy Living Foundation’s Free COVID-19 Support Program for Chronic Disease Patients and Their Families
  • Centers for Disease Control & Prevention’s Innovative Support for Patients with SARS-C0V-2 Infection Registry (INSPIRE):
  • Body Politic’s COVID-19 support group

References

  1. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. The Lancet. 2021 Jan 16;397(10270):220–232.
  2. Townsend L, Dowds J, O’Brien K, et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021 Jan 8. Online ahead of print.
  3. Salmon-Ceron D, Slama D, De Broucker T, et al. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study. J Infect. 2021 Feb;82:e1–e4.
  4. Nehme M, Braillard O, Alcoba G, et al. COVID-19 symptoms: Longitudinal evolution and persistence in outpatient settings. Annals of Intern Med. 2020 Dec 8;M20–5926. Online ahead of print.
  5. Lopez-Leon S, Wegman-Ostrosky T. Perelman C, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. MedRxiv preprint. 2021 Jan 30.
  6. Ramani SL, Samet J, Franz CK, et al. Musculoskeletal involvement of COVID-19: Review of imaging. Skeletal Radiol. 2021 Feb 18:1–11.
  7. Huang Y, Pinto MD, Borelli JL, et al. COVID symptoms, symptom clusters and predictors for becoming a long-hauler: Looking for clarity in the haze of the pandemic. medRxiv. 2021 Mar 5;2021.03.03.21252086. Preprint.
  8. Edwards E. Inside ‘post-COVID’ clinics: How specialized centers are trying to treat long-haulers. NBC News. 2021 Mar 1.
  9. Strosser JK, Yglesias R, Gaylis N, et al. Low incidence of coronavirus disease 2019 (COVID-19) infection in patients on biologic infusion therapies at a community rheumatology practice [abstract: 0435]. Arthritis Rheumatol. 2020 Oct;72(suppl 10).
  10. CytoDyn Inc. Study to evaluate the efficacy and safety of leronlimab for patients with severe or critical coronavirus disease 2019 (COVID-19) [NCT04347239]. CinicalTrials.gov. 2020 Nov 16.
  11. Hota B, Rush University Medical Center. Innovative support for patients with SARS-COV2 infections (COVID-19) registry (INSPIRE) [NCT04610515]. CinicalTrials.gov. 2021 Feb 24.
  12. Thomas Jefferson University. Investigating the long-term effects of COVID-19. Newswise. 2021 Feb 10.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Conditions Tagged with:coughCOVID-19dyspneafatigueneuropsychiatric

Related Articles

    The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

    November 23, 2021

    New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

    Research Helps Explain Idiosyncrasies of COVID-19

    November 23, 2021

    The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

    Bernard Chantal / shutterstock.com

    Diagnostic Challenges of MIS-C

    May 12, 2022

    During the peak of the coronavirus pandemic in Washington, D.C., we were asked to evaluate a 14-year-old boy admitted to the pediatric hospitalist service. He had been healthy until two weeks before, when he noted a sore throat, and soon after he developed fevers and rashes without congestion, shortness of breath, conjunctivitis or swollen lymph…

    Serological Antibody Tests in COVID-19: Test Reliability and Utility

    June 10, 2020

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences